(Q38588141)

4 September 2017

title

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies (English)

1 reference

4 September 2017

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Serena Pellegatta

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Gaetano Finocchiaro

series ordinal

1

1 reference

4 September 2017

publication date

16 September 2015

1 reference

Cancer Immunology, Immunotherapy

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

101-109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

Hallmarks of Cancer: The Next Generation

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Cell therapies in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Dendritic cell immunotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Clinical use of dendritic cells for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Perspectives for immunotherapy in glioblastoma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Heterogeneity maintenance in glioblastoma: a social network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Glioma in 2014: unravelling tumour heterogeneity-implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Immunobiological characterization of cancer stem cells isolated from glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Hypoxia potentiates glioma-mediated immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Glioma cancer stem cells induce immunosuppressive macrophages/microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

NK cells recognize and kill human glioblastoma cells with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Nestin Is Required for the Proper Self-Renewal of Neural Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1754-9

10.1007/S00262-015-1754-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1012723761

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377689%20AND%20SRC:MED&resulttype=core&format=json